Director, Investor Relations

About Jade Biosciences Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody candidate, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Role Overview Jade Biosciences is seeking a Director, Investor Relations to help build and execute a high caliber investor relations function for a publicly traded biotechnology company. The Director will play a central role in communicating Jade’s strategy, pipeline, scientific rationale, clinical development progress, financial position, and value proposition to a primarily investor audience, including institutional investors, sell-side analysts, bankers, and other capital markets stakeholders. This role requires a strong understanding of biotechnology equity markets, clinical-stage company strategy, and investor-facing communications. The ideal candidate will be able to translate complex scientific, clinical, regulatory, and financial information into clear, credible, and compelling messaging for sophisticated external audiences. Former sell-side biotechnology research professionals are encouraged to apply, including candidates who served as research associates supporting biotechnology or healthcare coverage. This is a remote role reporting to the Chief Financial Officer and will require periodic travel for investor conferences, investor roadshows, medical and scientific meetings, company meetings, and Board or leadership events. Key Responsibiliti